Becton, Dickinson and Company (NYSE:BDX - Free Report) - Equities researchers at William Blair reduced their Q4 2025 earnings per share (EPS) estimates for shares of Becton, Dickinson and Company in a note issued to investors on Monday, July 14th. William Blair analyst A. Brackmann now expects that the medical instruments supplier will earn $3.99 per share for the quarter, down from their prior estimate of $4.17. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Becton, Dickinson and Company's current full-year earnings is $14.43 per share. William Blair also issued estimates for Becton, Dickinson and Company's Q1 2026 earnings at $3.23 EPS, Q2 2026 earnings at $3.55 EPS, Q3 2026 earnings at $3.78 EPS and Q4 2026 earnings at $4.20 EPS.
A number of other analysts have also recently weighed in on the company. Morgan Stanley dropped their price target on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Wall Street Zen cut Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research report on Friday, May 2nd. Wells Fargo & Company cut Becton, Dickinson and Company from an "overweight" rating to an "equal weight" rating in a research report on Thursday, May 1st. Raymond James Financial cut Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Friday, May 2nd. Finally, Stifel Nicolaus lowered their target price on Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $219.22.
Check Out Our Latest Stock Analysis on BDX
Becton, Dickinson and Company Stock Performance
Shares of Becton, Dickinson and Company stock traded down $0.08 on Tuesday, reaching $178.23. 4,159,475 shares of the company were exchanged, compared to its average volume of 2,125,967. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.64 and a current ratio of 1.13. The company's 50-day moving average is $173.02 and its two-hundred day moving average is $205.02. The firm has a market cap of $51.08 billion, a price-to-earnings ratio of 34.01, a P/E/G ratio of 1.35 and a beta of 0.25. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, topping analysts' consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to analysts' expectations of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The business's quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.17 EPS.
Becton, Dickinson and Company Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Stockholders of record on Monday, June 9th were paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.33%. The ex-dividend date of this dividend was Monday, June 9th. Becton, Dickinson and Company's dividend payout ratio is presently 79.39%.
Insider Buying and Selling at Becton, Dickinson and Company
In other news, EVP David Shan sold 1,166 shares of the firm's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president directly owned 4,575 shares of the company's stock, valued at $783,194.25. This trade represents a 20.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.36% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Becton, Dickinson and Company
Large investors have recently modified their holdings of the stock. Hillsdale Investment Management Inc. boosted its holdings in Becton, Dickinson and Company by 1.7% during the fourth quarter. Hillsdale Investment Management Inc. now owns 3,060 shares of the medical instruments supplier's stock valued at $694,000 after purchasing an additional 50 shares in the last quarter. Northcape Wealth Management LLC boosted its holdings in Becton, Dickinson and Company by 0.5% during the first quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock valued at $2,248,000 after purchasing an additional 51 shares in the last quarter. Alpha Omega Wealth Management LLC boosted its holdings in Becton, Dickinson and Company by 5.7% during the first quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock valued at $225,000 after purchasing an additional 53 shares in the last quarter. Brady Family Wealth LLC boosted its holdings in Becton, Dickinson and Company by 1.2% during the first quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock valued at $989,000 after purchasing an additional 53 shares in the last quarter. Finally, Diversified Trust Co boosted its holdings in shares of Becton, Dickinson and Company by 4.7% in the 1st quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock worth $272,000 after acquiring an additional 53 shares in the last quarter. 86.97% of the stock is owned by institutional investors.
About Becton, Dickinson and Company
(
Get Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
